eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2025-10-09 18 August Spl Edition 66707 article Hriday Kumar Biswas 1 Kanhaiya Kumar Jha 1 Vikash Jakhmola 2 Srishti Morris 1 Pallavi Pandey 2 Anshika Rawat 1 Department of Pharmaceutics, Uttaranchal Institute of Pharmaceutical Science, Uttaranchal University, Prem Nagar, Dehradun, Uttarakhand, India. Department of Pharmaceutical Chemistry, Uttaranchal Institute of Pharmaceutical Science, Uttaranchal University, Prem Nagar, Dehradun, Uttarakhand, India. Artificial Intelligence (AI) is revolutionizing the field of neurology by significantly enhancing disease detection, therapeutic strategies, and patient management. Neurological disorders such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis have traditionally been challenging to diagnose and treat due to their complex and heterogeneous nature. Recent advancements in AI, particularly in machine learning and deep learning, enable the analysis of neuroimaging, electroencephalogram (EEG) signals, and genomic data with high precision, facilitating early and more accurate diagnoses. Beyond diagnostics, AI contributes to the development of personalized treatment plans by integrating a patient’s genetic information, medical history, and lifestyle factors. This personalized approach improves therapeutic outcomes and minimizes adverse effects. Wearable AI-powered devices further enhance care by allowing continuous, real-time monitoring of cognitive and motor functions, enabling timely clinical interventions and adjustments in treatment protocols. Moreover, AI is transforming the drug discovery landscape. It assists in identifying novel therapeutic targets, predicting drug responses, repurposing existing drugs, and optimizing clinical trial design, thus reducing the time and cost involved in bringing new treatments to market. Despite its enormous promise, the widespread clinical integration of AI faces challenges such as data privacy concerns, the need for transparent decision-making algorithms, and the establishment of standardized regulatory frameworks. This review explores the evolving applications of AI in neurogenetics and neurology, emphasizing its role in early diagnosis, precision medicine, long-term monitoring, and drug development. Continued interdisciplinary collaboration is essential to harness AI’s full potential in improving neurological healthcare outcomes. https://biomedpharmajournal.org/vol18octoberspledition/integrating-ai-with-neurogenetics-applications-in-precision-medicine-for-neurological-disorders/ Alzheimer's disease Epilepsy Neurogenetics Repurposing Sclerosis